Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Non-invasive prostate cancer treatment

Key ingredients to thwart the growth of prostate cancer found in certain foods

When you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving — or even preventing — cancer.

New research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.

Published online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.

“After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,” says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin. “The beauty of this study is that we were able to inhibit tumor growth in mice without toxicity.”

During the past decade, some cancer research has highlighted the potential therapies found in plants, including chemicals found in foods such as turmeric, apple peels and green tea. These compounds minimize one of the risk factors for cancer, inflammation within the body. People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.

The researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient. The most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.

“These nutrients have potential anti-cancer properties and are readily available,” says Tiziani. “We only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.”

The new research paper also demonstrates how the plant-based chemicals work together. Combining ursolic acid with either curcumin or resveratrol prevents cancer cells from gobbling something that they need to grow, glutamine. This is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.


Story Source:

Materials provided by University of Texas at Austin. Note: Content may be edited for style and length.


Journal Reference:

  1. Alessia Lodi, Achinto Saha, Xiyuan Lu, Bo Wang, Enrique Sentandreu, Meghan Collins, Mikhail G. Kolonin, John DiGiovanni, Stefano Tiziani. Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism. npj Precision Oncology, 2017; 1 (1) DOI: 10.1038/s41698-017-0024-z

Read this article on Science Daily: University of Texas at Austin. “Starving prostate cancer with what you eat: Apple peels, red grapes, turmeric.” ScienceDaily. ScienceDaily, 6 June 2017. www.sciencedaily.com/releases/2017/06/170606112750.htm.

Hal & Mary: Another Happy HIFU Story

Posted on HIFU Prostate Services 5/27/2017

If you ask Hal Plimpton, he will tell you that he is a semi-retired, international logistics consultant who has owned and operated his own business for many years.

If his wife, Mary, happens to hear him say he is “semi” retired, she will laugh and probably roll her eyes. “He was supposed to retire 15 years ago, but he’s still working,” said Mary.

However, one thing that Hal and Mary can agree on is that they made a good treatment decision several years ago when Hal was diagnosed with prostate cancer.

“I could tell that he felt really good about HIFU (high intensity focused ultrasound). He had confidence in the technology that it was going to work. I was a little nervous about all the unknowns, but ultimately I knew that if he felt good about it he would have a good experience – so I felt good about it too, “ said Mary.

Hal may have ultimately been confident in HIFU, but it wasn’t a conclusion he came to without doing a lot of research first – and connecting with a lot of people.

Mary and Hal’s prostate cancer journey included ups and downs that finally led them to the right decision for Hal but their experience with diagnosis and research on treatments was extensive – and in some respects, disconcerting.

“I followed my PSA for many years with my family doctor but in February of 2011, he referred me to a urologist for a biopsy,” said Hal. The pathology report indicated that he had prostate cancer with a Gleason score of 7.

“The first urologist we saw outlined several traditional treatments including surgery and radiation; I felt really uncomfortable with what I heard about the potential side effects,” said Hal.

“We were given some brochures and told to read them and decide what we wanted to do,” Mary said. “At that point, we went into research mode

“We saw a handful of doctors and it was not pleasant, informative or reassuring,” said Mary. “The physicians were focused on conventional treatment options, and we felt like each of them was trying to sell us on a specific treatment that they were personally invested in. It was very disheartening.”

“We found one book that had a single page about HIFU. Hal is kind of an ‘early adopter,’ and he was intrigued. But a urologist we spoke with was dismissive.” Mary said.

Coincidentally, Mary and Hal talked to a neighbor who connected them to a friend who had had a successful HIFU procedure some 5 years previously in Canada. Hal was able to talk to him at length and felt a heightened interest in the technique.

Mary was also learning more about HIFU. Curious about this new-to-them technology which she knew was of interest to Hal. She Googled the topic, picked up the phone, and called a company called, USHIFU in North Carolina. She was connected to a nurse, Karen, who was teamed with Dr. Michael Lazar, the then-sole HIFU-trained urologist in northern California.

Karen was wonderful. Our conversation was educational, but more than that she was a sympathetic ear,” said Mary. “She sent me a packet of information and before long we had an appointment to see Dr. Lazar.”

Meeting with Dr. Lazar was very different than their experiences with the other doctors they had seen. “He was so open and empathetic. He answered all our questions and was just very informative,” said Hal.

“He was was not selling any one particular approach. It was a very different kind of appointment from others we’d had,” added Mary.

Hal had HIFU with Dr. Lazar in Puerto Vallarta, Mexico in June of 2011 (HIFU wasn’t available in the U.S. outside of a clinical trial until after October 2015). A couple of friends accompanied them to PV for moral support – and one ended up having HIFU himself a few months later, also with Dr. Lazar.

“I might have opted for something more conventional but I knew this is what HAL WANTED, and, to me, I felt that if he believed in it, that elevated the likelihood of a positive outcome,” said Mary. “I cannot imagine that we could have had a better experience – in all respects – and it worked for us.”

Hal is happy to report that after HIFU, his PSA dropped from 7 to 0.1 and has stayed stable ever since. Almost more importantly, he had no adverse side effects.

“We are believers in HIFU for sure,” said Hal. “HIFU may not be ‘the answer’ for every man, but for families researching their options, we would urge you to consider HIFU. – And we cannot say enough good things about Dr. Lazar.”

By | May 31st, 2017|Dr. Michael Lazar, HIFU, News, Prostate Cancer|0 Comments

Doctor’s Own Prostate Cancer Diagnosis Leads to Early Intervention and Positive Results with HIFU

Dr. Michael Lazar of California HIFU shares the story of how friend and fellow surgeon Dr. Robert Pugach underwent HIFU treatment for prostate cancer following an early diagnosis with the disease.

Dr. Robert Pugach

It’s the news no man wants to hear from a doctor, “… you have prostate cancer.” And when you are a practicing physician who receives this news, all the more room for concern. Dr. Robert Pugach, medical director of Pacific Coast Urology Medical Center was diagnosed with prostate cancer last year and opted to undergo HIFU treatment with urologist and prostate cancer specialist Dr. Michael Lazar of California HIFU earlier this month. What transpired is truly an inspirational account of one man’s journey from diagnosis to cure. Dr. Pugach has chronicled his experience in a series of blog posts featured on the HIFU Prostate Services Website.

Following a cancer diagnosis by an internist and a follow-up biopsy with Dr. Lazar, Dr. Pugach opted to forgo the wait and watch approach most commonly prescribed for men testing with low levels of PSA. “I’m not a gambler, especially when it comes to my health,” he says. “I plan to live a long, healthy life.”

As a prostate cancer expert himself, Dr. Puach was all too aware of the potential for permanent urinary incontinence and erectile dysfunction with more conventional treatments, and was adamant about avoiding radiation due to the likelihood of a cancer recurrence in the future. Bolstered by his own experience with HIFU combined with positive results viewed first-hand with his own brother who underwent HIFU almost a decade earlier, Dr. Pauch was in the perfect frame of mind for pursing HIFU for himself.

In the weeks leading up to the procedure with Dr. Lazar and California HIFU, Dr. Pauch reasoned that there was absolutely nothing to fear, having been diagnosed early and having confidence in his doctor gave him a sense of empowerment over the disease.

“I had complete and total confidence in my doctor. I had the luxury of knowing Dr. Lazar well for 10 years when we travelled out of the country with our patients to treat their cancers with HIFU. When you watch someone in the OR, a fellow doctor like me can tell instantly what his skill level is. In Michael Lazar’s case, he is as good as one can get and is a true professional,” he explains.

HIFU: Non-invasive Treatment for Prostate Cancer

HIFU is a FDA approved precise and targeted therapy for the treatment of prostate cancer, that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of the sun to burn a leaf), the tissue temperature is raised only high enough to destroy the targeted tissue.

“Although recommendations are that most men opt to wait and watch when diagnosed with prostate cancer, HIFU is a treatment that is most effective for men who have early stage, localized prostate cancer that has not spread or metastasized outside the prostate,” explains Dr. Lazar. “As with Dr. Pugach the results are most promising when the cancer is caught while it is at the early, more treatable stage. That means; taking action relatively soon following the diagnosis.”

A happy ending to a terrifying diagnosis

On May 9th Dr. Pugach took a taxi to the San Francisco Surgery Center where Dr. Lazar performs HIFU. There the new patient was greeted by “… a wonderful and caring staff.” A short four hours later, the procedure is over and Dr. Lazar reported to the patient that all is well. “Dr. Lazar told me my procedure went perfectly – good words to hear!”

As most HIFU patients report, Dr. Pugach says there was no pain following the procedure and recovery was swift. “I learned that what I had always told my patients about how good they would feel afterwards was now proven to me to be true. Instead of having the common side effects of radical surgery, or contemplating seven weeks of radiation, I felt great…”

Dr. Pugach says he knows how good it feels to have a potentially serious or lethal disease diagnosed at a stage where it is less frightening to deal with. “I’ve learned how wonderful and enduring a good doctor-patient relationship can be and how a good bedside manner does more than many medications in helping a patient feel good.”

The moral of this story may well be to consider all of the options when dealing with prostate cancer, and although the temptation might be to put off routine screenings, early diagnosis might just save your life.

“Screening for prostate cancer is a simple process that allows us to look for cancer before any symptoms become obvious to the patient,” explains Dr. Lazar. “This process can help us discover the cancer at an earlier stage while the patient has the opportunity to take advantage of newer, less invasive options for treating prostate cancer such as HIFU.”

About California HIFU and Dr. Lazar

Dr. Michael Lazar is the only Northern California physician recognized as a leader in the use HIFU for prostate cancer. He has been successfully treating patients with HIFU since 2007. Dr. Lazar formed California HIFU in order to offer minimally invasive prostate cancer treatment to men with the Sonablate. For more information about HIFU treatment or to make an appointment call: (707) 546-5553 or visit our website: www.californiahifu.com.

Dr. Pugach’s full story “When the Doctor Becomes the Patient” may be viewed online in an ongoing series on the HIFU Prostate Services Website.

 

Focused ultrasound therapy is here: Are you ready?

A new, highly disruptive therapeutic technology called focused ultrasound is transforming – standards of care around the globe.

In this series, we asked speakers at the Milken Institute Global Conference to answer: How does one build a meaningful life in the age of technological disruption? Join the conversation by writing your own article here and including #MIGlobal.

A new, highly disruptive therapeutic technology called focused ultrasound is slowly but definitively influencing – and on the verge of transforming – standards of care around the globe. This game-changing, noninvasive treatment option for a wide variety of serious medical disorders has the potential to be an alternative or adjunct to surgery, radiation therapy, drug delivery, and cancer immunotherapy, while decreasing cost of care and improving outcomes for millions worldwide. If it sounds too good to be true, it isn’t. Focused ultrasound has been named one of the 50 greatest inventions by TIME magazine, credited with “changing medicine” by Fortune magazine, and just this month was named a top 10 clinical research achievement of 2016 by the Washington, DC-based Clinical Research Forum.

Innovation breeds innovation, but also, modification. Once fully developed and implemented – months to decades from now depending on the clinical indication – focused ultrasound will have widespread impact on healthcare constituents including physicians, treatment facilities, and manufacturers of legacy therapy equipment, among others. This process has in fact already begun. Focused ultrasound will also bring about major change to referral patterns, treatment paradigms, practice guidelines, and equipment acquisition as the technology transitions to a mainstream therapy.

In order to benefit from these changes, stakeholders – perhaps your organization or yourself – must be prepared to enter the field early on. And for many, “early on” means now.

What is focused ultrasound?

Focused ultrasound, or FUS, uses ultrasonic energy to target tissue deep in the body without incisions or radiation. With more than 22 regulatory approvals around the world to date, including five by the US Food and Drug Administration and more than 50 additional clinical indications in various (mostly early) stages of development, FUS may treat a disparate range of diseases including: Parkinson’s; Alzheimer’s; depression; obsessive-compulsive disorder; arthritis; back pain; and, tumors of the brain, breast, prostate, liver and pancreas. It has the potential to be as revolutionary to therapy as magnetic resonance scanning (MRI) has been to diagnosis.

The basic principle is analogous to using a magnifying glass to focus beams of sunlight on a single point to burn a hole in a leaf. With focused ultrasound, multiple intersecting beams of ultrasound energy are concentrated on a target deep in the body with extreme precision and accuracy (sparing adjacent normal tissue). Where each individual beam passes through the body there is no effect. But at the focal point where the beams converge, the focused ultrasound energy induces a variety of biologic effects including: destroying tissue, stimulating the body’s immune response, and enhancing the delivery of drugs. The location of the focal point and the treatment effect is guided and controlled in real time by ultrasound or MR imaging.

Besides patients, who will focused ultrasound affect?

Three healthcare industry groups will be particularly impacted by the widespread adoption of FUS. First, consider the manufacturers of legacy therapy equipment (e.g., linear accelerators for radiation therapy and robotic surgical devices) to which focused ultrasound is an existential threat. These manufacturers would be wise to begin redistributing resources from their traditional product lines now to invest in new FUS technology. Such companies are in fact well-positioned to do so as they already have the functioning sales, marketing, support and distribution channels in place. It is clear that once the medical community broadly understands the capabilities of focused ultrasound, many legacy therapy equipment options will quickly become obsolete.

Physicians will also benefit from entering the FUS field sooner rather than later. In the current environment, many physicians – not all – can unfortunately be motivated by money, time and outcome, in that order. As focused ultrasound advances, they will need to become educated and trained in utilizing FUS technology, and adopt it as part of their practice, even in cases where the economics on a per procedure basis are less favorable than current therapy alternatives. If they choose not to, patients seeking FUS – and demand is growing – will simply find a physician who will. Of note: focused ultrasound centers worldwide are reporting a backlog of several hundred essential tremor patients desiring FUS, and a nationwide study of nearly 1,000 US uterine fibroid sufferers (published in the October 2013 issues of both the American Journal of Obstetrics and Gynecology and the Journal of Women’s Health) found that when presented with fibroid treatment descriptions, the majority surveyed (60%) rated focused ultrasound as their top treatment choice.

Finally, now is also the time for hospitals and clinics to consider becoming early adopters of focused ultrasound. Doing so will enhance their reputation as being on the leading edge of medical care, and will provide a competitive differential over institutions that have not yet acquired FUS technology (see above regarding patient demand and preference). Additionally, offering focused ultrasound will create a halo effect for the hospital or clinic when patients are referred for this cutting-edge treatment and found to not be a candidate; these patients will often choose to stay with the practice and receive an alternative treatment, increasing market share for the institution.

The future is now

We are all aware that medical device development and adoption occurs exponentially; with focused ultrasound we are right now at the beginning of the inflection point of the curve. Our goal is to treat hundreds of thousands of patients annually and we are well on our way, with 15,000 FUS treatments performed worldwide in 2014, approximately 25,000 treatments in 2015, and a more than double increase to 50,000-plus patients treated in 2016. In other words, focused ultrasound is about to evolve into a robust medical field, with the pace of research and development, publications, patient treatments and the number of device manufacturers all increasing rapidly in the past few years.

Still, there remains an enormous amount of work to be done, and many barriers to overcome, before the technology becomes a standard of care that can help millions of patients. But we are closer than ever. When the potential of focused ultrasound is realized and it becomes a mainstream therapy, it will result in changes that will benefit countless patients and impact physicians, payers/providers, manufacturers, hospitals/clinics, caretakers, etc., around the globe. It’s coming. It is reinventing care. Are you ready?

Find out more at www.fusfoundation.org

About the Author: Neal F. Kassell, M.D., is the founder and chairman of the Focused Ultrasound Foundation. He was a Professor of Neurosurgery at the University of Virginia from 1984 until 2016 and was the Co-Chairman of the department until 2006. He received both his undergraduate and medical education at the University of Pennsylvania. In April 2016, Dr. Kassell was appointed by Vice President Joe Biden to the National Cancer Institute’s Blue Ribbon Panel for Cancer Moonshot Initiative. Dr. Kassell has contributed more than 500 publications and book chapters to the literature and is a member of numerous medical societies in the United States and abroad.

The Focused Ultrasound Foundation is a medical research, education, and advocacy organization created as the catalyst to accelerate the development and adoption of FUS, shortening the time from laboratory research to widespread patient treatment. 

By | May 4th, 2017|HIFU, News, Prostate Cancer|0 Comments

New Study: PSA levels in younger men might predict future risk of prostate cancer

mountain-bikers-in-brazil-1-1433086Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk.

Smarter screening strategies that can improve the accuracy of diagnosing lethal prostate cancer are urgently needed. Through a prospective study of US men, investigators from Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health have found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future risk of lethal prostate cancer later in life. Their findings suggest that screening PSA levels in men at mid-life may help identify those who are at greater risk and should be monitored more closely.

“We found a single baseline PSA-level measurement during midlife could accurately predict future risk of lethal prostate cancer,” said co-lead author Mark Preston, MD, MPH, a physician in BWH’s Division of Urology. “These data identify subgroups of men, based on their PSA levels at a given age, who could benefit from screening intervals tailored to their actual magnitude of risk.”

Read the full story here …

Dr. Michael Lazar, a Santa Rosa urologist and prostate cancer expert, is the only Northern California physician recognized as a leader in the use of high-intensity focused ultrasound (HIFU) for prostate cancer. He has been successfully treating patients with HIFU since 2007. Dr. Lazar now offers a HIFU Program in partnership with HIFU Prostate Services, LLC (HPS). HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). HIFU prostate treatments are performed at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport. For more answers on HIFU visit this page ...  For more information about HIFU treatment or to make an appointment call: (707) 546-5553.

By | June 21st, 2016|News, Prostate Cancer, Urology|0 Comments

California HIFU and Dr. Michael Lazar Recognizes Men’s Health Month With a Look at Prostate Cancer

California HIFU and Dr. Michael Lazar are helping to recognize Men’s Health Month by providing some valuable information and resources for men on Prostate Cancer. The idea behind Men’s Health Month is to heighten the awareness of preventable health problems like prostate cancer, and to encourage early detection and treatment. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation.

Informed Decision Making

your-questions-answeredAccording to The Center for Disease Control and Prevention (CDC) it is important for men to be aware of prostate cancer risks and to make informed decisions. This happens best when a man—

  • Understands the nature and risk of prostate cancer.
  • Understands the risks of, benefits of, and alternatives to screening.
  • Participates in the decision to be screened or not at a level he desires.
  • Makes a decision consistent with his preferences and values.

The CDC as well as other federal agencies follow the prostate cancer screening recommendations set forth by the U.S. Preventive Services Task Force, which recommends against prostate specific antigen (PSA)-based screening for men who do not have symptoms. Other organizations, like the American Urological Association,[PDF-310KB] the American Cancer Society, and the American College of Physicians may have other recommendations. It is important to talk to a doctor and get routine screenings.

Some men may be having prostate problems and want to learn more about prostate cancer symptoms and risk factors, the PSA screening test, and conditions that are not cancer such as an enlarged prostate (BPH) and prostatitis. To learn more follow this link for practical lists, tips, and medical images …

Knowing your prostate cancer therapy options empowers you to make smart choices

Prostate cancer is the leading solid organ cancer in the USA and the second most common cause of cancer related death. Worldwide, it is the fourth most common cancer with differing biologic activity in different cultures, probably related to different lifestyles. Many prostate cancers can be managed conservatively, especially in elderly men. But larger tumors, those with higher Gleason score and higher (and rising) PSA levels, especially in younger men, should be treated more aggressively.

Prostate Cancer Therapy Options

There are many options available to residents of Northern California. Prostate cancer is usually managed with active surveillance, radiation therapy, surgery to remove the cancerous gland, freezing (cryotherapy), or high intensity focused ultrasound (HIFU). Hormonal therapy is used to control cancer that has spread beyond the prostate and is no longer curable, or for very elderly patients with a limited life expectancy.

High Intensity Focused Ultrasound (HIFU)

HIFU is a FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation.

HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a magnifying glass focusing the rays of the sun to burn a leaf), the tissue temperature is raised to 90 degrees Celsius, destroying the targeted tissue.

Learn more about HIFU treatment for prostate cancer …

By | June 14th, 2016|News, Prostate Cancer|0 Comments

Focal Therapy For Prostate Cancer

hifu mini article cropped-logo-square.jpgFocal therapy, often referred to as a “male lumpectomy,” is a general term for a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its normal tissue

As technology has advanced, physicians now have the ability to diagnose patients with prostate cancer earlier which means that often times tumors within the prostate are small and contained to the prostate.

Advanced imaging techniques, allow doctors to pinpoint exactly where the tumor within the prostate is located using multi-parametric MRI and UroNav fusion biopsies, enabling them to target only the tumor within the prostate, leaving other tissue unharmed.

Focal therapy is being studied all over the world because of the large potential for reducing side effects such as urinary incontinence and erectile dysfunction. Additionally, due to the noninvasive nature of focal therapy, treatment and recovery times are dramatically reduced.

Read this article on HIFU Prostate Services.

For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com.

New Study Reveals Prostate Cancer Metastasis Risk Higher in Some AS Patients

Metastases develop in a small proportion of patients placed on active surveillance (AS) for prostate cancer (PCa), but the risk is significantly higher in some men than others, such as those with Gleason 7 tumors, a new study found.

In a study of 980 men placed on AS—769 with low-risk and 211 with intermediate-risk PCa—a team led by Laurence Klotz, MD, of Sunnybrook Health Sciences Centre in Toronto found that 30 men (3%) progressed to metastatic disease at a median of 6.3 year after diagnosis, according to study findings published in The Journal of Urology (2016;195:1409-1414). Metastases developed in 13 (10%) of 133 patients with Gleason 7 disease.

Metastases occurred in 16 low-risk and 14 intermediate-risk patients, and developed in bone in 18 patients and lymph nodes in 13. Of the 30 men, 15 died from PCa, 4 died of other causes, and 11 are alive with metastases.

Patients with intermediate-risk disease were at higher risk for metastasis, but those with Gleason score 6 and PSA level greater than 10 ng/mL were not at increased risk.

In multivariate analysis, a PSA doubling time less than 3 years versus greater than 3 years was associated with a 3.7-fold increased risk of metastasis. Gleason score 7 compared with 6 was associated with a 3-fold increased risk. The presence of 3 or more positive biopsy cores was associated with a 2.7-fold increased risk compared with fewer positive cores.

The authors concluded that AS appears safe in patients at low risk and in select patients at intermediate risk, particularly those with Gleason score 6 and PSA levels greater than 10 ng/mL. The presence of Gleason pattern 4 on diagnostic biopsy was associated with a 3-fold to 4-fold increased risk of metastasis. Patients with Gleason pattern 4 should be offered active surveillance with caution, according to the investigators.

In editorial comments accompanying the new report, Michael O. Koch, MD, of the Indiana University School of Medicine in Indianapolis, said Dr. Klotz and his colleagues contribute to the growing body of knowledge of the usefulness of AS for managing PCa, but observed: “While the authors have highlighted the risk factors for developing metastases in patients treated with AS, they may be overly optimistic about the safety of this management strategy, particularly in patients with Gleason 7 disease.”

Dr. Koch pointed out that the median follow-up was only 6.3 years, so the number of patients with Gleason 7 disease in whom metastases will develop will grow even more. “As of now AS would appear to be ill-advised in this group of patients,” he noted.

Source: http://www.renalandurologynews.com

For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

See this article on Renal & Urology News …

By | April 13th, 2016|HIFU, News, Urology|0 Comments

HIFU San Francisco – Meet Dr. Michael Lazar

HIFU 4.12 pic 1.2Michael J. Lazar, MD was an early user of the HIFU technology dating back to 2007.  He was credentialed as proctor in 2010 and participated in editing the user manual for the Sonablate HIFU system. Lazar trained FDA investigators on HIFU patient care and was commissioned by SonaCare Medical to proctor FDA clinical trial cases.  He has treated or been involved with over 200 patients and is also site director for SonaCare Medical’s international training site in Puerto Vallarta, Mexico.

Dr. Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, Calif. since 1983.  He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Dr. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital.  He has participated in medical staff leadership and has served as hospital chief-of-staff and well as departmental and section chairs.  Dr. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

California HIFU

Dr. Lazar formed California HIFU in order to offer minimally invasive prostate cancer treatment to men with the Sonablate. He performs HIFU at HIFU Center of Excellence In San Francisco, 450 Sutter Street, Suite 500, San Francisco, CA 94108

HIFU Center of Excellence offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment. For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

See more on the HIFU Prostate Services website.

By | April 12th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments

HIFU Center of Excellence in San Francisco

HIFU 4.12 pic 1Sonablate HIFU is available now with Dr. Michael Lazar at HIFU Center of Excellence In San Francisco located in downtown San Francisco, 450 Sutter Street, Suite 500, San Francisco, CA 94108

HIFU Center of Excellence offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment. For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com

HIFU 4.12 pic 1.2Physician Practicing HIFU in San Francisco: Dr. Michael Lazar

See more on the HIFU Prostate Services Website.

By | April 12th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments